 |
Vol.56 No.4 contents | Japanese/English |
 | Full Text of PDF (625K) Article in Japanese |
- Case Report -
Successful Pemetrexed Rechallenge Chemotherapy in Advanced Pulmonary Adenocarcinoma
Toshi Murakami1, 2, Kiyoshi Makihata3, Nagio Takigawa41Department of Respiratory Medicine, Onomichi Municipal Hospital, Japan, 2Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Japan, 3Makihata Clinic, Japan, 4Department of General Internal Medicine 4, Kawasaki Medical School, Japan
Objective. Pemetrexed is an effective agent for the treatment of non-squamous non-small cell lung cancer; however, the effectiveness of pemetrexed rechallenge chemotherapy remains to be proven. We administered pemetrexed rechallenge chemotherapy when disease progression was observed in advanced lung cancer patients in whom disease control had been achieved with initial pemetrexed treatment. Methods. We retrospectively reviewed five patients with advanced lung adenocarcinoma who had received pemetrexed rechallenge chemotherapy between January 2010 and December 2014. Results. All of the patients (median age, 64 years; range, 61-76) had stage IV lung adenocarcinoma. Four patients responded to the initial pemetrexed-based chemotherapy and stable disease was achieved in one patient. The median interval from the end of initial pemetrexed-based chemotherapy to pemetrexed rechallenge chemotherapy was 14.5 months (range, 11.8-17.4 months). Three patients achieved a partial response, and the median progression free survival period was 7.2 months (95% confidence interval, 3.8-10.6 months) with pemetrexed rechallenge chemotherapy. Conclusion. Pemetrexed rechallenge chemotherapy may be useful for selected patients.
key words: Pulmonary adenocarcinoma, Pemetrexed, Rechallenge
Received: December 11, 2015
Accepted: April 21, 2016
JJLC 56 (4): 273-277, 2016
